Biotech Values

[mcbio]

Re: TH-302 pancreatic cancer data

I breifly read the TH-302 results for their combo trial and noticed the pancreatic cancer arm TH-302 + gemcitabine combo trial had a complete response and a number of CR's. I hav no position in THLD at the moement - but would enjoy hearing comments on the results.

It wasn't a controlled trial so it very well could have been the gemcitabine itself that was entirely responsible for the CR and the additional PRs. There's no way of knowing until a controlled Phase 2 is done if TH-302 is an active drug.